Ripretinib
INVICTUS
Deciphera Pharmaceuticals · Phase 3 · Completed · Enrollment 129
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Ripretinib 150 mg | GIST after imatinib, sunitinib and regorafenib | 150 mg | ITT | placebo | median progression-free survival (BICR): 6.3 months, primary analysisprogression-free survival hazard ratio vs placebo: 0.15 HR, primary analysisobjective response rate (BICR): 9%, primary analysismedian overall survival: 15.1 months, not tested for significance |
| Placebo | GIST after imatinib, sunitinib and regorafenib | placebo | ITT | n/r | median progression-free survival (BICR): 1 months, primary analysismedian overall survival: 6.6 months, 66% switched to ripretinib |